10-Q: Longevity Health Holdings Reports Q1 2025 Results, Navigates Merger and Nasdaq Compliance

Longevity Health Holdings announces its Q1 2025 financial results, highlighting the Elevai Skincare acquisition and ongoing efforts to regain Nasdaq compliance amidst a proposed merger with 20/20 Biolabs.

Summary

• Longevity Health Holdings reported a net loss of $1.51 million for Q1 2025, compared to a net loss of $3.27 million in Q1 2024.
• Gross sales for Q1 2025 were $534,943, primarily from the Elevai Skincare acquisition.
• The company completed the Elevai Skincare acquisition on January 16, 2025, adding approximately $2.5 million in revenue in 2024.
• Operating expenses decreased due to cost-cutting measures, including the termination of certain executives.
• The company is pursuing a merger with 20/20 Biolabs and a concurrent financing to raise at least $4 million.
• Longevity Health Holdings is working to regain compliance with Nasdaq listing requirements, including a minimum bid price and market value of listed securities.
• A reverse stock split of 1:30 was effected on May 12, 2025, to address Nasdaq compliance.
• The company is facing a lawsuit related to convertible notes, with potential damages exceeding $4 million.
• There is substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive developments, such as the Elevai Skincare acquisition and cost-cutting measures, the company is facing significant financial challenges and uncertainty about its future. The going concern warning and the ongoing litigation are major concerns.

Positives

• The net loss decreased significantly compared to the same period last year.
• The Elevai Skincare acquisition is contributing to revenue.
• The company is actively pursuing a merger to enhance its business prospects.
• Cost-cutting measures have been implemented to reduce operating expenses.
• The company is taking steps to regain compliance with Nasdaq listing requirements.

Negatives

• The company is still experiencing net losses and negative cash flow from operations.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is involved in a lawsuit with potential damages exceeding $4 million.
• The company has failed to regain compliance with Nasdaq listing requirements by the initial deadlines.
• The merger is subject to conditions and may not be completed.

Risks

• Failure to complete the merger with 20/20 Biolabs could result in a $2 million termination fee and harm the stock price.
• The company may not be able to raise the required $4 million in financing for the merger.
• The company may not be able to regain compliance with Nasdaq listing requirements, leading to delisting.
• The lawsuit related to convertible notes could have a material adverse effect on the company's financial condition.
• Economic uncertainty and geopolitical tensions could negatively impact the company's business and financial condition.
• The company's reliance on a small number of employees to facilitate the merger poses a risk.

Future Outlook

The company is focused on completing the merger with 20/20 Biolabs, raising additional capital, and regaining compliance with Nasdaq listing requirements. Management anticipates that revenue from the continued commercialization of its cosmetic products and the anticipated cost savings from the restructuring activities will assist us in extending our cash runway.

Industry Context

The bio-aesthetics industry is competitive, with companies focused on longevity and healthy aging. The merger with 20/20 Biolabs is intended to strengthen Longevity Health Holdings' position in the market.

Comparison to Industry Standards

• It is difficult to compare Longevity Health Holdings directly to industry standards due to its unique combination of bio-aesthetics and regenerative medicine assets.
• Comparable companies in the bio-aesthetics space include Allergan Aesthetics (a subsidiary of AbbVie), Galderma, and Merz Aesthetics, which have significantly larger revenue bases and market capitalizations.
• The company's focus on exosomes and secretomes aligns with current trends in the skincare industry, but its financial performance lags behind industry leaders.
• The proposed merger with 20/20 Biolabs is a strategic move to diversify its product offerings and potentially improve its financial stability.

Legal Proceedings

• Puritan Partners LLC v. Carmell Regen Med Corporation et al., No. 655566/2023 (New York Supreme Court, New York County), alleging breach of obligations under convertible notes and warrants, with potential damages totaling $2,725,000 through November 1, 2023, plus additional fees and interest.

Related Party Transactions

• A member of the Company's board of directors is a managing partner of the Placement Agent for the 2025 Private Placement.

Stakeholder Impact

• Shareholders face the risk of dilution and potential delisting from Nasdaq.
• Employees face uncertainty due to the merger and potential cost-cutting measures.
• Customers may be affected by changes in product offerings and pricing.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• Complete the merger with 20/20 Biolabs.
• Raise additional capital through equity or debt issuances.
• Regain compliance with Nasdaq listing requirements.
• Continue commercialization of cosmetic products.
• Explore out-licensing of certain research and development programs.

Key Dates

Keywords

merger, acquisition, Nasdaq compliance, financial results, reverse stock split, litigation, going concern, Elevai Skincare, 20/20 Biolabs, Longevity Health Holdings